Rohann Correa (@drcorrearo) 's Twitter Profile
Rohann Correa

@drcorrearo

Radiation Oncologist at London Health Sciences Centre & Assistant Professor, Western University, London, Ontario

ID: 1058519436896825344

calendar_today03-11-2018 00:41:14

166 Tweet

541 Followers

539 Following

Shankar Siva (@_shankarsiva) 's Twitter Profile Photo

Rohann Correa gives a ‘tour de force’ overview of the history of #radiotherapy for #kidneycancer. The evidence is building considerably over time. Hilarious opening slide shouting out the IROCK consortium. Looking forward to IROCK launch in 2 hours! shorturl.at/fmsBL #kcsm

<a href="/DrCorreaRO/">Rohann Correa</a> gives a ‘tour de force’ overview of the history of #radiotherapy for #kidneycancer. The evidence is building considerably over time. Hilarious opening slide shouting out the IROCK consortium. Looking forward to IROCK launch in 2 hours! shorturl.at/fmsBL
#kcsm
Rohann Correa (@drcorrearo) 's Twitter Profile Photo

Congrats Aadel Chaudhuri, MD PhD on this exciting work, was my pleasure to discuss at #ASTRO23. Look forward to continuing our chat on where we go from here! @drdavidpalma

Lucas C Mendez (@lucascmendez) 's Twitter Profile Photo

Now online IJROBP - The Red Journal Early results of the randomized Hope trial. Is ultra-HypoRT to the pelvis post prostate BT as well tolerated as conventional RT? sciencedirect.com/science/articl… Alfonso Gomez-Iturriaga Dr Kevin Martell Dr Stanley Liu

Rohann Correa (@drcorrearo) 's Twitter Profile Photo

🙏🏽🙏🏽 Ben Slotman Great to see you again and I was proud to give a well-deserved nod of appreciation to immune analysis expert Dr. @SchneidersFamke & Amsterdam UMC - collaborative studies are ongoing!

Vivian Tan MD (@drviviantan) 's Twitter Profile Photo

🔥Hot off the press European Urology Oncology IROCK 🇨🇦🇦🇺🇺🇸🇩🇪🇯🇵 demonstrating #SABR ⚡️yields moderate long-term renal function decline, low dialysis rates even in patients with a solitary kidney #radonc authors.elsevier.com/c/1jOzs9Cfv--d… Thankful for mentors Shankar Siva Alex Louie MD, PhD Rohann Correa

🔥Hot off the press <a href="/EurUrolOncol/">European Urology Oncology</a> 

IROCK 🇨🇦🇦🇺🇺🇸🇩🇪🇯🇵 demonstrating #SABR ⚡️yields moderate long-term renal function decline, low dialysis rates even in patients with a solitary kidney #radonc

authors.elsevier.com/c/1jOzs9Cfv--d…

Thankful for mentors <a href="/_ShankarSiva/">Shankar Siva</a> 
<a href="/DrAlexLouie/">Alex Louie MD, PhD</a> <a href="/DrCorreaRO/">Rohann Correa</a>
OncoAlert (@oncoalert) 's Twitter Profile Photo

The OncoAlert 🚨Newsletter NOW OUT Covering July 5-11. 2024 REGISTER at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅UNICANCER-PRODIGE23🧪 in #RectalCancer ✅Renal function after SABR in 1ry #KidneyCancer Vivian Tan MD Alex Louie MD, PhD Rohann Correa

Simon Lo (@simonlo21054188) 's Twitter Profile Photo

Stereotactic Body Radiotherapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide - ScienceDirect sciencedirect.com/science/articl…

Laura Bukavina (@laurabukavinamd) 's Twitter Profile Photo

Rohann Correa reviews the indications and outcomes of SBRT in T1 tumors, highlighting the evolving perspectives on radiation therapy and its results. We are all excited to see more in the near future SIU-Urology #SIU2024NewDelhi

<a href="/DrCorreaRO/">Rohann Correa</a> reviews the indications and outcomes of SBRT in T1 tumors, highlighting the evolving perspectives on radiation therapy and its results. We are all excited to see more in the near future <a href="/SIU_urology/">SIU-Urology</a> #SIU2024NewDelhi
Shankar Siva (@_shankarsiva) 's Twitter Profile Photo

"Oligo"-no more! 🇨🇦ARREST phase I out now IJROBP - The Red Journal - Sue Yom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏

"Oligo"-no more! 🇨🇦ARREST phase I out now <a href="/IJROBP/">IJROBP - The Red Journal</a> - <a href="/sueyom/">Sue Yom</a> 
➡️SABR to median=16 "poly"metastases in patients  who had already exhausted multiple lines of systemic therapy
➡️4x dose levels (up to 6Gyx5). 
➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏